XELPROS (latanoprost ophthalmic emulsion) 0.005%, a translucent ophthalmic emulsion, is a topical formulation of latanoprost, a prostaglandin analogue that is used as first-line treatment for open-angle glaucoma or ocular hypertension. If contact lenses are worn, they should be removed prior to administration of the solution.

AAOPT/WCO attendees are invited to visit Sun Ophthalmics at Booth #1409 in Exhibit Hall WO1. The long-term effects of increased pigmentation are not known.

Eyelash Changes: XELPROS may gradually cause changes to eyelashes, vellus hair in the treated eye including increased length, thickness, pigmentation and number of lashes. Other adverse reactions reported in 1% to 5% of the patients were eye irritation, blepharitis urinary tract infection, headache, and bronchitis. Use with Contact Lens: Contact lenses should be removed prior to administration of XELPROS and may be reinserted 15 minutes following administration. The recommended dosage of XELPROS is one drop in the affected eye(s) once daily in the evening. Dry Eye Patient and Physician Survey Presentations

Apply to Ophthalmic Technician, Account Manager, Ophthalmic Assistant and more! Sun Ophthalmic News Get the latest news from Sun Ophthalmics. Established in 2015, Sun Ophthalmics is backed by Sun Pharma, a multinational pharmaceutical company. After discontinuation of XELPROS iris pigmentation is likely to be permanent. Read more .

CEQUA provides the highest FDA-approved concentration of cyclosporine A (CsA) and is the first and only approved CsA product that incorporates a nanomicellar technology. Posted 3 minutes ago. Pigmentation is expected to increase as long as XELPROS is administered. If you have any questions about Sun Pharma Products, please contact Sun Pharma Customer Service at 1-800-818-4555. XELPROS is contraindicated in patients with known hypersensitivity to latanoprost, or any other ingredients in this product. We are leading the way through the development of innovative technologies for eye care professionals.

We are leading the way through the development of innovative technologies for eye care professionals.Sun Ophthalmics is a division of Sun Pharmaceutical Industries, Inc. If such drugs are used, they should be administered at least five (5) minutes apart. Macular Edema: XELPROS should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. CEQUA (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic use is commercialized in the U.S. by Sun Ophthalmics, the branded ophthalmics division of Sun Pharma’s wholly owned subsidiary. Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment. CEQUA (cyclosporine ophthalmic solution) is a patented, novel, proprietary nanomicellar formulation of cyclosporine A, 0.09% in a clear, preservative-free, aqueous solution. We are with you every step of the way—offering comprehensive support and partnership at every turn.We share your passion for specialty eye care.

A different approach. Pigmentation: XELPROS may cause changes to pigmented tissues.

In a prior Phase 2b/3 clinical trial with 455 patients, CEQUA demonstrated increased tear production (p<0.01) and was well tolerated by the study population. Sun Ophthalmics is committed to reenergizing eye care. Reduction of IOP starts approximately 3 to 4 hours after administration and the maximum effect is reached after 8 to 12 hours.
Less than 1% of patients discontinued therapy because of intolerance to these adverse events.
CEQUA (cyclosporine ophthalmic solution) 0.09%, for topical ophthalmic use is commercialized in the U.S. by Sun Ophthalmics, the branded ophthalmics division of Sun Pharma’s wholly owned subsidiary.

Details on the poster presentations at AAOPT/WCO are as follows (all posters will be presented in Exhibit Hall WO1 of the Orange County Convention Center):

The most frequently reported changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes.

We recognize that the ophthalmic industry is missing the partnership of years past when professionals and eye care companies came together to work toward a common vision.Sun Ophthalmics is committed to reenergizing eye care.



Sun Ophthalmics to present updated CEQUA and XELPROS data at the 2019 American Academy of Optometry (AAOPT) meeting in Orlando, Fla., Oct. 23-27 With a strong foundation of research and innovation, Sun Pharma has more than 30 years of global experience in bringing more than 2,000 products and innovations to the healthcare community.